Pfizer

Showing 15 posts of 894 posts found.

11149low_reception_in_darm

Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod

March 1, 2018
Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical

Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …

finland_flag

Pfizer taps real world evidence for CVD in new partnership

February 14, 2018
Research and Development BC Platforms, Pfizer, biotech, cardiovascular disease, drugs, pharma, pharmaceutical

BC Platforms, a company that focuses on genomic data managements and analysis, has announced that it has partnered with Pfizer …

gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

Pfizer teams up with Indian Government to battle antimicrobial resistance

January 31, 2018
Medical Communications, Research and Development India, Pfizer, antimicrobial resistance, pharma

Pfizer has entered into a partnership with the Indian Council of Medical Research (ICMR) in an effort to fight antimicrobial …

pfizer-building-logo1web

Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer

January 19, 2018
Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

barrett_novartis

Novartis prises Pfizer’s Oncology Head away

January 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Pfizer, biotech, drugs, pharma, pharmaceutical

Novartis has been looking to find someone to fill the shoes of Bruno Strigini since it was revealed that he …

Pfizer exits neuroscience R&D space

January 8, 2018
Research and Development, Sales and Marketing Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …

pfizer_chrome_plate

Pfizer makes $830m drug discovery pact with Arvinas

January 4, 2018
Research and Development, Sales and Marketing Arvinas, Pfizer, biotech, drugs, pharma, pharmaceutical

Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing …

Pfizer headquarters

NICE to take another look at Pfizer’s leukaemia drug

January 2, 2018
Manufacturing and Production, Sales and Marketing NICE, Pfizer, biotech, drugs, pharma, pharmaceutical

Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …

Pfizer’s Bosulif scores US green light in leukaemia sub-type

December 21, 2017
Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma

Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …

merck_and_co

MSD and Pfizer receive approval for combo diabetes therapy

December 21, 2017
Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical

MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …

FDA approves Pfizer’s Xeljanz for psoriatic arthritis

December 18, 2017
Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …

What will Pfizer do with its second Remicade biosimilar?

December 14, 2017
Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …

The Gateway to Local Adoption Series

Latest content